ZA200203704B - Pharmaceutical formulations containing zolmitriptan. - Google Patents

Pharmaceutical formulations containing zolmitriptan.

Info

Publication number
ZA200203704B
ZA200203704B ZA200203704A ZA200203704A ZA200203704B ZA 200203704 B ZA200203704 B ZA 200203704B ZA 200203704 A ZA200203704 A ZA 200203704A ZA 200203704 A ZA200203704 A ZA 200203704A ZA 200203704 B ZA200203704 B ZA 200203704B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical formulations
formulations containing
zolmitriptan
containing zolmitriptan
formulation
Prior art date
Application number
ZA200203704A
Other languages
English (en)
Inventor
Alan Roy Dearn
Simon John Summers
Sarah Louise Williamson
Trevor John Coomber
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10865629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200203704(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200203704B publication Critical patent/ZA200203704B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA200203704A 1999-12-03 2002-05-09 Pharmaceutical formulations containing zolmitriptan. ZA200203704B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9928578.5A GB9928578D0 (en) 1999-12-03 1999-12-03 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ZA200203704B true ZA200203704B (en) 2003-10-29

Family

ID=10865629

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200203704A ZA200203704B (en) 1999-12-03 2002-05-09 Pharmaceutical formulations containing zolmitriptan.

Country Status (28)

Country Link
US (2) US6750237B1 (enExample)
EP (1) EP1237551B1 (enExample)
JP (1) JP2003515559A (enExample)
KR (1) KR100670092B1 (enExample)
CN (1) CN1222287C (enExample)
AT (1) ATE291914T1 (enExample)
AU (1) AU778092B2 (enExample)
BR (1) BRPI0016138B8 (enExample)
CA (1) CA2392050C (enExample)
CZ (1) CZ301528B6 (enExample)
DE (1) DE60019162T2 (enExample)
EE (1) EE05305B1 (enExample)
ES (1) ES2236001T3 (enExample)
GB (2) GB9928578D0 (enExample)
HK (2) HK1048442B (enExample)
HU (1) HU229458B1 (enExample)
IL (2) IL149578A0 (enExample)
IS (1) IS2135B (enExample)
MX (1) MXPA02005319A (enExample)
NO (1) NO322119B1 (enExample)
NZ (1) NZ518862A (enExample)
PL (1) PL200679B1 (enExample)
PT (1) PT1237551E (enExample)
RU (1) RU2255736C2 (enExample)
SK (1) SK287228B6 (enExample)
UA (1) UA75059C2 (enExample)
WO (1) WO2001039772A1 (enExample)
ZA (1) ZA200203704B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations
SE0102855D0 (sv) * 2001-08-27 2001-08-27 Astrazeneca Ab Method of treatment
EP1744784A2 (en) * 2004-05-11 2007-01-24 Becton, Dickinson and Company Formulations of anti-pain agents and methods of using the same
WO2005115345A1 (en) * 2004-05-28 2005-12-08 Imaginot Pty Ltd Oral therapeutic compound delivery system
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
US20060211751A1 (en) * 2004-11-19 2006-09-21 Reuven Izsak Zolmitriptan crystal forms
CN100341504C (zh) * 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20100048609A1 (en) * 2006-08-01 2010-02-25 Jacobs Jeffrey W Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid
DE602007013440D1 (de) * 2006-10-19 2011-05-05 Auspex Pharmaceuticals Inc Substituierte indole
KR101517415B1 (ko) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
AU2011316225B2 (en) 2010-10-15 2016-05-19 Contera Pharma Aps Combinations of serotonin receptor agonists for treatment of movement disorders
JP6121734B2 (ja) * 2012-02-09 2017-04-26 久光製薬株式会社 マイクロニードル用ゾルミトリプタン含有コーティング組成物及びマイクロニードルデバイス
BR112014025907B1 (pt) 2012-04-18 2023-02-14 Contera Pharma Aps Formulação farmacêutica disponível para administração por via oral adequada para manejo aprimorado de transtornos do movimento
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
KR101624049B1 (ko) 2014-10-29 2016-05-24 연세대학교 산학협력단 사카린을 이용한 용해도를 증가시킨 약제학적 조성물
CN108135916B (zh) * 2015-06-19 2022-01-28 北京科辉智药生物科技有限责任公司 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用
WO2017122161A1 (en) 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
AU2017297718B2 (en) 2016-07-11 2023-06-08 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
CN111432801A (zh) * 2017-12-21 2020-07-17 台湾微脂体股份有限公司 缓释型曲普坦组合物及通过皮下或类似途径使用其的方法
US20210322343A1 (en) 2020-04-15 2021-10-21 Farzana Shaheen Nasally administered pharmaceutical composition for the treatment of epilepsy and related disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT97888B (pt) * 1990-06-07 1998-12-31 Zeneca Ltd Processo para a preparacao de compostos heterociclicos derivados de indol e de composicoes farmaceuticas que os contem
GB9012672D0 (en) * 1990-06-07 1990-08-01 Wellcome Found Therapeutic heterocyclic compounds
GB9516145D0 (en) * 1995-08-07 1995-10-04 Wellcome Found Improved chemical synthesis
IL127955A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
GB2315673A (en) * 1996-08-01 1998-02-11 Merck & Co Inc Treatment of migraine
EP1014943B1 (de) * 1997-02-05 2002-06-19 Jago Research Ag Medizinische aerosolformulierungen
GB9928578D0 (en) * 1999-12-03 2000-02-02 Zeneca Ltd Pharmaceutical formulations

Also Published As

Publication number Publication date
ES2236001T3 (es) 2005-07-16
IS2135B (is) 2006-08-15
EE200200283A (et) 2003-06-16
UA75059C2 (uk) 2006-03-15
PL357597A1 (en) 2004-07-26
GB2373726A (en) 2002-10-02
IL149578A (en) 2008-04-13
KR20020058051A (ko) 2002-07-12
CA2392050C (en) 2009-11-24
NO20022525D0 (no) 2002-05-28
PT1237551E (pt) 2005-07-29
NZ518862A (en) 2004-02-27
BRPI0016138B8 (pt) 2021-05-25
ATE291914T1 (de) 2005-04-15
SK287228B6 (sk) 2010-03-08
HU229458B1 (en) 2013-12-30
NO20022525L (no) 2002-05-28
NO322119B1 (no) 2006-08-14
US7220767B2 (en) 2007-05-22
GB9928578D0 (en) 2000-02-02
AU778092B2 (en) 2004-11-18
PL200679B1 (pl) 2009-01-30
SK7532002A3 (en) 2002-12-03
WO2001039772A1 (en) 2001-06-07
BR0016138B1 (pt) 2013-09-10
EP1237551B1 (en) 2005-03-30
US20040214899A1 (en) 2004-10-28
HUP0203597A3 (en) 2005-07-28
GB0214845D0 (en) 2002-08-07
CA2392050A1 (en) 2001-06-07
JP2003515559A (ja) 2003-05-07
HK1048442A1 (en) 2003-04-04
CZ301528B6 (cs) 2010-04-07
DE60019162T2 (de) 2006-02-02
DE60019162D1 (de) 2005-05-04
KR100670092B1 (ko) 2007-01-17
HK1048445A1 (en) 2003-04-04
CZ20021901A3 (cs) 2002-11-13
RU2255736C2 (ru) 2005-07-10
AU1715701A (en) 2001-06-12
CN1222287C (zh) 2005-10-12
IS6394A (is) 2002-05-24
CN1402636A (zh) 2003-03-12
HK1053430A1 (en) 2003-10-24
EP1237551A1 (en) 2002-09-11
US6750237B1 (en) 2004-06-15
MXPA02005319A (es) 2002-12-06
IL149578A0 (en) 2002-11-10
HUP0203597A2 (hu) 2003-02-28
HK1048445B (en) 2005-08-26
EE05305B1 (et) 2010-06-15
BR0016138A (pt) 2002-08-06
HK1048442B (zh) 2005-05-13
RU2002117649A (ru) 2004-01-27
GB2373726B (en) 2004-10-20

Similar Documents

Publication Publication Date Title
GB2373726B (en) Pharmaceutical formulations containing zolmitriptan
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
GB0005251D0 (en) Therapeutic compounds
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
MY119403A (en) Novel compounds with analgesic effect.
MY129356A (en) Electrospun pharmaceutical compositions
MY132705A (en) Novel compounds with analgesic effect
GB0031088D0 (en) Medicaments
IS1907B (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
AU7315301A (en) Compounds and compositions for delivering active agents
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
HUP0301349A2 (hu) IL-11-tartalmú készítmények
SE9802208D0 (sv) Novel compounds
IL115589A0 (en) Use of cck-b antagonists in pharmaceutical compositions
IL141914A0 (en) Dosage form comprising liquid formulation
AU2001289606A1 (en) Dry powder formulation comprising racecadotril
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
SE0001916D0 (sv) Novel formulation
PL348202A1 (en) Pharmaceutically active composition and dispensing device
AP2000001950A0 (en) Paroxetine maleate.
ES2131482A1 (es) Formulacion acuosa de bambuterol.
NZ508292A (en) Treatment of migraine symptoms with ibuprofen and salts thereof
ES2159479A1 (es) Nuevos indazoles como inhibidores de la ciclooxigenasa-ii
DE60004819D1 (de) 10-formyltetrahydrofolate dehydrogenase als therapeutischen mittel